Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Insider Sells $800,777.88 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) insider Ross Moat sold 27,594 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $29.02, for a total value of $800,777.88. Following the sale, the insider now directly owns 9,415 shares of the company's stock, valued at approximately $273,223.30. The trade was a 74.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Ross Moat also recently made the following trade(s):

• On Monday, May 5th, Ross Moat sold 6,272 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $28.00, for a total value of $175,616.00.
• On Tuesday, April 29th, Ross Moat sold 64,035 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $25.21, for a total value of $1,614,322.35.
• On Thursday, May 1st, Ross Moat sold 23,234 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $28.02, for a total transaction of $651,016.68.
• On Monday, April 21st, Ross Moat sold 18,259 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $20.29, for a total value of $370,475.11.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock traded up $0.40 during trading hours on Friday, hitting $29.92. 516,835 shares of the company were exchanged, compared to its average volume of 500,410. The company has a 50 day simple moving average of $24.10 and a two-hundred day simple moving average of $21.84. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $29.98. The firm has a market cap of $2.18 billion, a P/E ratio of -213.73 and a beta of 0.06.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. During the same quarter last year, the firm posted ($0.25) EPS. Kiniksa Pharmaceuticals's revenue was up 72.5% compared to the same quarter last year. As a group, sell-side analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Institutional Trading of Kiniksa Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its position in shares of Kiniksa Pharmaceuticals by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after buying an additional 568 shares during the period. US Bancorp DE bought a new stake in Kiniksa Pharmaceuticals during the 1st quarter worth approximately $33,000. Asset Management One Co. Ltd. purchased a new stake in Kiniksa Pharmaceuticals in the 1st quarter worth approximately $41,000. Wealthquest Corp bought a new position in Kiniksa Pharmaceuticals in the 1st quarter valued at $42,000. Finally, Lazard Asset Management LLC bought a new stake in Kiniksa Pharmaceuticals during the fourth quarter valued at $61,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on KNSA shares. Citigroup began coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a "buy" rating and a $40.00 price objective on the stock. Wedbush restated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Finally, Jefferies Financial Group lifted their target price on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $38.80.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.